Pd37-09 prevalence of bone density deficiencies in men presenting for hypogonadism treatment: do we need to worry?

You have accessJournal of UrologySexual Function/Dysfunction/Andrology: Medical and Non-Surgical Therapy I1 Apr 2015PD37-09 PREVALENCE OF BONE DENSITY DEFICIENCIES IN MEN PRESENTING FOR HYPOGONADISM TREATMENT: DO WE NEED TO WORRY? Joseph Ellen, Igor Sorokin, Clay Mechlin, Charles Welliver, and Andrew McCullough Joseph EllenJoseph Ellen More articles by this author , Igor SorokinIgor Sorokin More articles by this author , Clay MechlinClay Mechlin More articles by this author , Charles WelliverCharles Welliver More articles by this author , and Andrew McCulloughAndrew McCullough More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2015.02.2271AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Introduction: Hypogonadism is a known risk factor in men with osteoporosis. The prevalence of hip osteoporosis in men with total testosterone deficiency (<300ng/dL) is 4.3%. Therefore, it is recommended that baseline bone mineral density (BMD) studies be obtained in this population. The urologist is referred a unique population of men with varying degrees of hypogonadism in various age groups. Objective: To identify the rate of osteopenia and osteoporosis and the predictive risk factors associated with low BMD scans in hypogonadal men and hypogonadal men. METHODS A retrospective review of 235 consecutive patients with clinical hypogonadism (both symptoms and biochemical testosterone deficiency <300ng/dL) had BMD scans performed on a single Dual-energy X-ray Absorptiometry DEXA machine (Hologic 4500). Osteopenia was defined as a femoral neck, total hip, or total spine BMD T-score between -1 and -2.5. Osteoporosis was defined as a BMD T-score of -2.5 or less. Duration of hypogonadism was defined as time from 1st laboratory value noting low testosterone to BMD scan. Mean testosterone values were obtained from all recorded testosterone values from diagnosis of hypogonadism to BMD scans. Recorded risk factors for analysis included diabetes, smoking history, BMI, duration of hypogonadism. RESULTS For all patients the mean age of our cohort was 50.7 ±12.5 years. Average duration of hypogonadism was 1219 days. We found normal BMD in 56% of patients, osteopenia in 39%, and osteoporosis in 5%. For our patients, BMI was significantly protective against bone changes. Sex hormones, previous treatment, diabetes, or duration of hypogonadism were not predictive of abnormal BMD scans. CONCLUSIONS There is a very high rate of osteopenia and osteoporosis in all male patients with hypogonadism referred to a urologist. This study reiterates the importance of obtaining BMD scans on all male patients with clinical hypogonadism. © 2015 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 193Issue 4SApril 2015Page: e773 Advertisement Copyright & Permissions© 2015 by American Urological Association Education and Research, Inc.MetricsAuthor Information Joseph Ellen More articles by this author Igor Sorokin More articles by this author Clay Mechlin More articles by this author Charles Welliver More articles by this author Andrew McCullough More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...